 Product
BGC 945
Indication
Solid tumours
Phase
Late preclinical
Description
Novel thymidylate synthase inhibitor that is selectively transported into tumour cells via the alpha-folate receptor.
BTG is currently seeking a licensing partner for BGC 945. For more information, please contact us.
Return to Pipeline
|